1-3 of 3
Roger Belizaire
Close
Sort by
Journal Articles

Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome

Adriana Chiaramida, Sandra G. Obwar, Anja E. H. Nordstrom, Maria Ericsson, Aisha Saldanha, Elena V. Ivanova, Gabriel K. Griffin, Dilshad H. Khan, Roger Belizaire
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7445–7456.
https://doi.org/10.1182/bloodadvances.2023010531
Published: 2023
Includes: Supplemental data
Journal Articles

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy

Jurjen Versluis, Manu Pandey, Yael Flamand, J. Erika Haydu, Roger Belizaire, Mark Faber, Rahul S. Vedula, Anne Charles, Kevin M. Copson, Shai Shimony, Alon Rozental, Pavan K. Bendapudi, Ofir Wolach, Elizabeth A. Griffiths, James E. Thompson, Richard M. Stone, Daniel J. DeAngelo, Donna Neuberg, Marlise R. Luskin, Eunice S. Wang, R. Coleman Lindsley
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2835–2846.
https://doi.org/10.1182/bloodadvances.2021006166
Published: 2022
Includes: Supplemental data
Journal Articles

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease

Clinical Trials & Observations
Roger Belizaire, Haesook T. Kim, Samuel J. Poryanda, Nikola V. Mirkovic, Evelyn Hipolito, William J. Savage, Carol G. Reynolds, Marie J. Fields, Jennifer Whangbo, Tomohiro Kubo, Sarah Nikiforow, Edwin P. Alyea, Philippe Armand, Corey S. Cutler, Vincent T. Ho, Bruce R. Blazar, Joseph H. Antin, Jerome Ritz, Robert J. Soiffer, John Koreth
Journal: Blood Advances
Blood Adv (2019) 3 (7): 969–979.
https://doi.org/10.1182/bloodadvances.2018029124
Published: 2019
Includes: Supplemental data